NCCN

The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.

The company highlighted growth in demand for its test , and is now ramping up marketing and focusing on its IVD development plans.

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The network said MDxHealth's ConfirmMDx should be used to screen men at higher risk for prostate cancer despite a negative biopsy. 

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development a

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.

The National Comprehensive Cancer Network now supports MGMT methylation testing in elderly glioblastoma patients to assess the likelihood that they will benefit from temozolomide treatment. This may help spur adoption of MDxHealth's MGMT PredictMDx for Glioblastoma test.

This article has been updated to correct that Ellen Matloff is a plaintiff in AMP v. USPTO.

Pages

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.